BIOGEN INC. BIIB revenue by segment, product and geography
In its fiscal year ending 2025-12-31, BIOGEN INC. reported revenue across 1 business segments; the largest, Reportable Segment, was $9.89B, 100.0% of the filed sum (+2.2% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$9.89B100.0%+2.2% yoy
Members sum to the consolidated $9.89B for this period.
- Product$7.12Bshare n/a-1.3% yoy
- MS Product Revenues$4.04Bshare n/a-7.1% yoy
- Rare Disease Product Revenue$2.15Bshare n/a+8.4% yoy
- Revenues From Anti CD20 Therapeutic Programs$1.86Bshare n/a+6.3% yoy
- Tysabri Product$1.67Bshare n/a-2.9% yoy
- SPINRAZA$1.55Bshare n/a-1.7% yoy
- Fumarate$1.43Bshare n/a-10.6% yoy
- Royalty Attributed To OCREVUS$1.41Bshare n/a+5.6% yoy
- +21 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Reportable Segment$2.74B100.0%+3.4% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.